Amyloidosis
Therapeutic area
Metabolic Disease
Rare disease
Yes
- Definition
- A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Amyloidosis
- Therapeutic area
- Metabolic Disease
- amyloidosis
- amyloid
- amyloid disease
- amyloidoses
- amyloidosis
- amyloidosis (disease)
- All therapeutic areas
- Metabolic Disease
- Severity
- Severe
- MONDO ID
- MONDO:0019065
- Parent condition
- MONDO:0021179
Related records
Broader conditions (6)
- Disease
- Disease by developmental or physiological process
- Disease by molecular mechanism
- Human disease
- Metabolic disease
- Proteostasis deficiencies
Narrower conditions (52)
- AA amyloidosis
- AApoAI amyloidosis
- AApoAIV amyloidosis
- ABeta amyloidosis, Arctic type
- ABeta amyloidosis, dutch type
- ABeta amyloidosis, Iowa type
- ABeta amyloidosis, Italian type
- ABeta2M amyloidosis
- ABetaA21G amyloidosis
- ABetaL34V amyloidosis
- ABri amyloidosis
- ACys amyloidosis
- ADan amyloidosis
- AFib amyloidosis
- AH amyloidosis
- AL amyloidosis
- ALECT2 amyloidosis
- ALys amyloidosis
- Alzheimer disease type 1
- Amyloidosis bronchopulmonary
Trials (302)
- [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
- [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
- 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
- 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
- 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
- A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
- A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
- A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
- A Non-interventional Cohort Safety Study of Patients With hATTR-PN
- A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- A Phase 3 Study of NTLA-2001 in ATTRv-PN
- A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
- A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
- A PILOT Study on LSGB vs EMB in the Diagnosis of Cardiac Transthyretin Amyloidosis
- A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
- A Registry of AL Amyloidosis (ReAL)
- A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
Approved drugs (5)
- Acoramidis hydrochloride
- Inotersen sodium
- Patisiran sodium
- Tafamidis
- Tafamidis meglumine
Drugs in development (31)
- Acoramidis Phase 1
- Anselamimab Phase 1
- APG-2575 Phase 1
- Belantamab mafodotin Phase 1
- Birtamimab Phase 2
- Carfilzomib Phase 1
- Cyclophosphamide Phase 3
- Daratumumab Phase 3
- Dexamethasone Phase 3
- Dezamizumab Phase 2
- Doxycycline Phase 2
- Eplontersen Phase 1
- Eplontersen sodium Phase 1
- Eprodisate disodium Phase 3
- GSK-294 Phase 1
- Ibrutinib Phase 2
- Idelalisib Phase 2
- Inotersen Phase 3
- Iodine I124 evuzamitide Phase 2
- Lenalidomide Phase 3
Other linked drugs (3)
- Bortezomib
- Diflunisal
- Ixazomib citrate